Structure and Function of Hib Pili from Haemophilus influenzae Type b
نویسندگان
چکیده
منابع مشابه
Immunogenicity and Efficacy of Different Haemophilus influenzae type b Vaccines
Haemophilus influenzae, a major cause of meningitis in young children leading to death and other neurological sequelae. The disease leaves 15 to 35% of the survivors with permanent disabilities, such as, mental retardation or deafness. Despite the availability of new and more powerful antibiotics children with Hib meningitis still suffer from high mortality or morbidity. The emergence of multir...
متن کاملReactivity of Haemophilus influenzae type b anti-pili antibodies.
The reactivity of anti-pilus antibodies to native and denatured Haemophilus influenzae b (Hib) pili was studied using rabbit serum prepared against piliated H. influenzae b strain M43 (p+) and adsorbed with its non-piliated variant, strain M42 (p-). The specificity of the adsorbed serum for Hib pili was documented by immunogold electron microscopy and by immunoprecipitation, which revealed the ...
متن کاملComparison of hemagglutinating pili of Haemophilus influenzae type b with similar structures of nontypeable H. influenzae.
Thirty-eight clinical isolates of nontypeable Haemophilus influenzae were tested for the presence of hemagglutinating pili similar to those of H. influenzae type b (Hib) that mediate buccal epithelial cell adherence. Four endogenously hemagglutinating (HA+) strains were identified, and eight additional HA+ variants were obtained from HA- strains by erythrocyte enrichment. All 12 HA+ nontypeable...
متن کاملHaemophilus Influenzae B
یکی از شایع ترین مننژیت باکتریایی در شیرخواران، هموفیلوس آنفلوانزا از نوع B (HIB) می باشد. به منظور تهیه و عرضه واکسنی جهت حفظ کودکان در مقابل این بیماری به بازار جهانی، تحقیقاتی انجام و نوعی واکسن در بخش تحقیقاتی آکسفورد مورد آزمایش و ارزیابی قرار گرفت تا در صورت تمایل والدین و کارکنان بهداشتی، تجویز همزمان آن با واکسن سه گانه و فلج اطفال عملی گردد.
متن کاملLicensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine.
On August 19, 2009, the Food and Drug Administration (FDA) licensed Hiberix (GlaxoSmithKline Biologicals, Rixensart, Belgium), a Haemophilus influenzae type b (Hib) conjugate vaccine composed of H. influenzae type b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]) conjugated to inactivated tetanus toxoid (PRP-T). Hiberix is licensed for use as the booster (final) dose of the Hib va...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Bacteriology
سال: 2002
ISSN: 0021-9193,1098-5530
DOI: 10.1128/jb.184.17.4868-4874.2002